Repository logo
Communities & Collections
All of DSpace
  • English
  • العربية
  • বাংলা
  • Català
  • Čeština
  • Deutsch
  • Ελληνικά
  • Español
  • Suomi
  • Français
  • Gàidhlig
  • हिंदी
  • Magyar
  • Italiano
  • Қазақ
  • Latviešu
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Српски
  • Svenska
  • Türkçe
  • Yкраї́нська
  • Tiếng Việt
Log In
New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Odemis, Ilker"

Filter results by typing the first few letters
Now showing 1 - 6 of 6
  • Results Per Page
  • Sort Options
  • No Thumbnail Available
    Item
    Cases of Multisystem Inflammatory Syndrome in Adults (MIS-A) Associated with SARS-CoV-2 Infection
    (2022) Demiroglu, Yusuf Ziya; Oruc, Ebru; Odemis, Ilker; Bilgel, Ziya Gokalp; 0000-0003-2638-0163; AAD-1638-2019
    Multisystem inflammatory syndrome in adults (MIS-A) is a rare condition that develops after coronavirus disease 2019 (COVID-19). We present two young adult male patients, aged 25 and 24 years, who admitted to our outpatient clinic with high fever, redness in the eyes, diarrhea, and maculopapular rash four weeks after after clinically mild COVID-19 infection. Echocardiography showed global hypokinesia in both cases. Therefore, the history of COVID-19 should be questioned, and the patient should be evaluated for possible MIS-A, especially when new heart failure is detected during the pandemic.
  • No Thumbnail Available
    Item
    The Diagnostic Value of Monocyte Chemoattractant Protein-1, Compared with Procalcitonin, C-reactive Protein, and Lactate in Bacteremia Estimation for Patients with Febrile Neutropenia
    (2020) Odemis, Ilker; Kose, Sukran; Senger, Suheyla Serin; Akbulut, Ilkay; Celik, Didem; 0000-0003-2638-0163
    Bacteremia in the febrile neutropenic patients significantly increases the mortality. It takes a long time to complete the blood culture for the diagnosis of bacteremia. Therefore, quick and specific markers are needed for the prediction of bacteremia. The purpose of this study are to compare the diagnostic value of lactate, procalcitonin, C-reactive protein (CRP) and monocyte chemoattractant protein-1 (MCP-1) levels in a patient with febrile neutropenia, and to evaluate its usefulness in predicting bacteremia. This study was designed to be prospective case-control study. Forty-eight patients and forty control cases aged 18 years or older who were monitored between May 2016 and May 2017 were included in the study. P-value as <0.05 was accepted to be significant. Significantly increased values were determined by the level of inflammatory markers of patients compared to the control group. The highest diagnostic odds ratio were found to be in MCP-1. For patients with febrile neutropenia, CRP (83.3%), and MCP-1 (81.2%) were the most sensitive markers while lactate (85.0%), MCP-1 (75%), and procalcitonin (75%) were the most specific markers. CRP was the only beneficial biomarker in the estimation of bacteremia. No significant results were observed for any biomarker for the prediction of the gram positive/negative discrimination of bacteria in the blood culture. We believe that CRP MCP-1, and lactate levels can be taken into consideration for diagnosis, and CRP can be beneficial in the estimation of bacteremia.
  • No Thumbnail Available
    Item
    IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered Patients with COVID-19
    (2022) Yesilagac, Hasan; Aliskan, Hikmet Eda; Gumus, Hatice Hale; Odemis, Ilker; Unsal, Zuhal Ekici; 0000-0003-2638-0163; 0000-0001-9071-9606; AAD-1638-2019; AAJ-2108-2021
    Introduction: Since the Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) first emerged in Wuhan, on 12 December 2019, it has spread rapidly across the world and developed into a pandemic. As healthcare workers are frequently in contact with Coronavirus disease-2019 (COVID-19) patients, they can be affected more often than the general population. In this study we aimed to investigate the SARS-CoV-2 seroprevalence and the IgG antibody levels among healthcare workers who frequently encountered COVID-19 patients in our hospital.Materials and Methods: In total, 182 healthcare workers were identified from database and their data was retrospectively analyzed. Participants with previous PCR positivity, pregnant, autoimmune disease history or immunosuppressive treatment history were excluded. Participants were grouped depending on their frequency of contact with COVID-19 patients (high and medium risk). All the samples were tested simultaneously for anti-SARS-CoV-2-IgG antibodies by the ELISA method. A chi-square test was used to compare categorical variables. A t-test and an ANOVA test were carried out to where appropriate.Results: Serological testing of 182 HCWs exposed to SARS-CoV-2 patients illustrated that 13.2% of them (24 out of 182) might have experienced an asymptomatic or subclinical SARS-CoV-2 infection. High risk participants, anosmia, and ageusia were statistically significant risk factors. The rate of detection of antibody positivity among doctors (p=0.030) and patients with anosmia, and ageusia (p=0.047) were found significantly higher than the others. In addition, SARS-CoV-2 antibody ratio results were found significantly higher in the groups of high risk participants (p=0.046), patients with clinical signs (p=0.008), myalgia (p=0.039), anosmia, and ageusia (p=0.025), respectively.Conclusion: Our study showed that serological testing is useful for determining asymptomatic or subclinical infections prevelance of SARS-CoV-2 among those with close contact with COVID-19 patients. Serological tests can be helpful determining the prevelance COVID-19 infection, especially among the HCWs.
  • No Thumbnail Available
    Item
    Olfactory disorders in patients with mild to moderate COVID-19: spontaneous recovery in one-month follow up
    (2021) Inan, Serhat; Ozer, Fulya; Erbek, Selim Sermed; Caylakli, Fatma; Odemis, Ilker; Kursun, Ebru; 0000-0003-2638-0163; 0000-0001-5381-6861; 0000-0001-8821-4481; 0000-0002-7333-2896; AFK-3690-2022; AAJ-1407-2021; AAG-2486-2022; ABC-1809-2020; AAP-7195-2020
    Objective: In this study, we aimed to evaluate olfactory disorders (OD) and recovery processes in patients with coronavirus disease 2019 (COVID-19) infection at three time periods within one month from the time of diagnosis. Methods: A total of 96 patients with COVID-19 participated in the study. Self-reported changes in olfactory functions and their effects on quality of life (QoL) were evaluated using the National Health and Nutrition Examination Survey, the Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS), and Sino-Nasal Outcome Test (SNOT)-22. At the time of diagnosis, the patients were divided into three groups: anosmia, hyposmia, and no OD (control) group. Subsequently, olfactory functions were retested at the time of the first negative polymerase chain reaction (PCR) control test and one month from the time of diagnosis. Results: During the COVID-19 infection, 68.7% of patients had OD; of these, 37% had anosmia, and 29% had hyposmia. Dysgeusia was found in 44.8% of the patients. OD was the primary symptom in 10.8% of the patients. The QoL scores of those with anosmia and hyposmia were significantly lower than those with no OD in all three surveys (P <.05). The QOD-NS scores of those with OD lasting more than 14 days were significantly lower in all three surveys (P <.05). Of the patients with OD, 4.34% had no spontaneous recovery at the end of the first month. Conclusion: Recovery of OD is faster in patients with hyposmia than in those with anosmia. Although COVID-19related permanent OD is not commonly observed, treatment of OD that lasts for more than 15 days would be beneficial to avoid permanent sequelae.
  • No Thumbnail Available
    Item
    A rare case of cardiac alveolar echinococcosis without any complications for eight years
    (2022) Celik, Didem; Odemis, Ilker; Korkmaz, Metin; Kose, Sukran; 0000-0003-2638-0163; 34823349
  • No Thumbnail Available
    Item
    Two Case of Rhino-Orbito-Cerebral Mucormicosis Developed After COVID-19 Infection
    (2021) Demiroglu, Yusuf Ziya; Odemis, Ilker; Oruc, Ebru; Ozer, Fulya; Ulas, Burak; Canpolat, Emine Tuba; Yalcin, Cigdem; Sanli, Ozlem Oguc; 0000-0003-2638-0163; 0000-0001-5381-6861; 0000-0003-2638-0163; 0000-0002-6099-4786; 34666667; AAG-2486-2022; ABC-1809-2020; AFK-3690-2022
    Coronavirus 2019 (COVID-19) infection causes excessive cytokine response and a decrease in cellular immune response and this increases susceptibility to fungal co-infections. Mucormycosis is a rare, life-threatening invasive fungal infection. In this report, two cases who developed rhino-orbito-cerebral mucormycosis shortly after having COVID-19 infection were presented. The first case was a 68-year old woman who admitted to our clinic with orbital cellulitis in her left eye and had a known diagnosis of asthma and rheumatoid arthritis. She was diagnosed with COVID-19 pneumonia 40 days ago, stayed in the intensive care unit for a long time, and received pulse steroid (1000 mg methylprednisolone), interleukin-1 (IL-1) inhibitor (anakinra) and broad-spectrum antibiotic treatments together with antiviral therapy during this period. The second case was a 63-year-old male patient with known diabetes mellitus, hypertension and retinitis pigmentosa, with a history of hospitalization in the intensive care unit due to COVID-19 pneumonia 20 days ago and received pulse steroid therapy during this period. He admitted to our clinic with the complaints of droopy right eyelid, swelling, nausea and vomiting. In both cases, paranasal sinus tomography findings were consistent with invasive sinusitis. Functional endoscopic sinus surgery was performed immediately in less than 16 hours from the first admission in both cases. Histopathological examination of the both cases revealed results consistent with mucormycosis. Mucorales spp. was isolated in sinus tissue culture of the second case taken during the operation. Both of the patients received liposomal amphotericin B. First case died on the 19th day of the treatment. Second case was discharged with full recovery after nine weeks of treatment. The suppression of cellular immunity during the COVID-19 infection, and the use of steroids and interleukin inhibitors in the treatment of severe cases may increase secondary invasive fungal infections. Therefore, clinicians should more frequently consider possible fungal infections in patients with COVID-19.

| Başkent Üniversitesi | Kütüphane | Açık Bilim Politikası | Açık Erişim Politikası | Rehber |

DSpace software copyright © 2002-2026 LYRASIS

  • Privacy policy
  • End User Agreement
  • Send Feedback
Repository logo COAR Notify